Insights from 2023 ESGO Annual Meeting
ESGO 2023 Insights: "Final OS and Long-Term Safety in the ENGOT-OV16/NOVA Phase 3 Trial of Niraparib in Patients With Recurrent Ovarian Cancer"
By
Insights from 2023 ESGO Annual Meeting
FEATURING
Mansoor Raza Mirza
By
Insights from 2023 ESGO Annual Meeting
FEATURING
Mansoor Raza Mirza
Comments 0
Login to view comments.
Click here to Login
